Introduction
Profound advances in the fields of receptor biology and pharmacology have now identified novel approaches to modulate the function of G protein-coupled receptors (GPCRs), the largest super family of cell-surface receptors in the human genome [1, 2] . Although the concept of rational drug design has existed for decades, only recently have structural biology and molecular modeling capabilities advanced this concept beyond the theoretical stage. Providing a further boost is the related and exploding field of biased ligand pharmacology, whose insights have greatly advanced our understanding of qualitative GPCR signaling. One intriguing discovery 16 years ago was the identification that receptor intracellular surface loops that interact with G proteins can be targeted by N-terminal lipidated peptides (pepducins) to modulate GPCR signaling and potentially serve as therapeutics [1, 3] .
Current therapies to treat asthma and other airway diseases primarily include antiinflammatory agents and bronchodilators. Anti-inflammatory agents target trafficking and resident immunocytes and structural cells, while bronchodilators act to prevent or reverse shortening of airway smooth muscle (ASM), the pivotal tissue regulating bronchomotor tone. Unfortunately, about 50% of patients with asthma have inadequate control with current therapeutics [4] . Despite some refinements in the duration and specificity of β 2 -adrenergic receptor (β 2 AR) agonists and in the use of antagonists of contractile GPCRs in asthma, continued refinement may yield diminishing returns and truly novel approaches will be needed to overcome current limitations and address the needs of patients not served by currently available therapies.
Most bronchodilators are GPCR ligands which exert their action by either promoting prorelaxant or inhibiting pro-contractile signaling. This underscores the importance of the competitive balance of pro-relaxant and pro-contractile GPCR signaling in regulating ASM contractility and airway resistance in obstructive lung diseases [5] [6] [7] . Airway resistance is also affected by structural changes in the airways (airway remodeling) and pulmonary architecture as well as tissue mechanics, but GPCR ligands acting on ASM have the strongest impact on changes in airflow.
Increased levels of endogenous contractile GPCR agonists have been associated with allergic airway inflammation, leading to increased ASM contraction and airflow obstruction. One strategy to ameliorate this is to inhibit pro-contractile GPCR signaling by administering a small molecule antagonist of a pro-contractile receptor. This approach may be suboptimal or entirely ineffective when multiple GPCRs are activated to contract ASM. Treatment with β-agonists relaxes airways by antagonizing pro-contractile GPCRs at several loci in airway smooth muscle including transmembrane receptor signaling, calcium mobilization and flux, and distal regulation of contractile filaments through regulation of myosin light chain kinase/ phosphatase (MLCK/MLCP) activity. Therefore, use of β-agonists has an inherent advantage over selective antagonists of pro-contractile GPCRs as β-agonists dilate/protect airways irrespective of the type of pro-contractile stimulus. Even though inhaled β-agonists are the mainstay therapy for acute bronchospasm and combined long-acting β-agonist (LABA) and corticosteroid treatment is the cornerstone of asthma and chronic obstructive pulmonary disease (COPD) maintenance therapy, concerns about β-agonist efficacy and safety have persisted for decades. Chronic β-agonist use has been associated with β 2 AR tachyphylaxis [8] [9] [10] , loss of asthma control [11] [12] [13] , and death [14] [15] [16] [17] . Although associations of chronic β-agonist use with adverse events have not been uniquely observed in all studies [18] [19] [20] , the need for understanding mechanisms involved in detrimental effects of β-agonists on lung physiology and pathology remains.
Fortunately, recent basic science research in GPCR biology and pharmacology has discovered novel modes of GPCR signaling and regulation that potentially explains the complex effects of existing drugs while offering the promise of new, more efficacious drugs. In this review, we summarize studies based on newfound paradigms in GPCR biology to (1) identify strategies capable of making existing asthma and COPD drugs better; and (2) develop new drugs that work by distinctly different mechanisms.
Diverse receptor conformations are linked to differential signaling events;
arrestins and biased ligands can influence the qualitative nature of signaling GPCR ligands are often characterized based on their efficacy, be it positive or negative, to a specific signaling pathway that is in turn linked to a specific cellular function. However, it has been apparent for some time that there exists a much greater complexity of ligandreceptor interactions, and recent studies that attempt to explain 'why' are probably only scratching the surface of the regulatory phenomena that enable receptor dexterity. Numerous GPCRs exhibit significant diversity in their capacity to activate multiple signaling pathways, linked to either other G proteins or in a G protein-independent manner. Some ligands engage a receptor to induce a distinct receptor conformation capable of activating one signaling pathway while inhibiting another pathway. This phenomenon, referred to 'functional selectivity' or 'biased agonism', has been demonstrated for a number of GPCRs. The 5-HT 2C R ligand SB 242084, promoted 5-HT 2c R-mediated PLC activation [21] but inhibited 5-HT 2c R-mediated activation of phospholipase A2 (PLA 2 ) and the subsequent release of arachidonic acid (AA) [22] . In a somewhat striking observation, studies by Stout et al. [23] show that the agonist efficacy of ligands does not correlate with the capacity to induce desensitization of the different signaling pathways, therefore suggesting differential regulation of desensitization by various ligands of the 5-HT2cR. Similar observations have been made for 5-H 2A , µ-opioid, somatostatin, and chole-cystokinin receptors, where the level of efficacy of various ligands is dissociated from the ability to promote agonist-induced receptor desensitization (reviewed in [24] ). Studies of D2 [25] and D1 dopamine [26] , H1 histamine [27] and V2 vasopressin [24, 28] receptors have identified ligands that exhibit differential abilities in pathway activation and receptor desensitization and trafficking.
Agonism bias is also exhibited towards G protein-independent signaling. Arrestins have now become established as the most prominent G protein-independent signaling molecules (Figure 1 ). Arrestins were initially characterized as important regulators of receptor desensitization and internalization; arrestins are recruited to activated GPCRs where they subsequently hinder G protein recruitment and facilitate receptor internalization via clathrincoated pits [29] . More recently arrestins have been proposed to act as signaling scaffolds and a large body of evidence now supports the capacity of various ligands to promote β-arrestindependent signaling events in absence of G protein activation. ICI 118,551 and propranolol, both inverse agonists for β 2 AR-mediated G s activation, have been shown to induce β 2 ARmediated arrestin-dependent p42/p44 activation [30] . This differential efficacy has been observed for other receptors including the V2 vasopressin receptor [30] and the angiotensin-1 receptor [31] ; which both have the ability to activate p42/p44 via β-arrestin recruitment independent of G q activation when bound to their respective biased ligands.
Collectively, these findings demonstrate that GPCR ligands can induce a range of distinct receptor conformations which determine signaling outcomes. Wisler et al. [32] identified carvedilol as having a unique profile out of a panel of 16 βAR ligands: it is an inverse agonist for βAR-mediated G s signaling but stimulates receptor phosphorylation, recruits beta-arrestin, promotes receptor internalization and activates p42/p44 in an arrestindependent manner. The authors hypothesize that this unique profile contributes to the effectiveness of carvedilol in treatment of heart failure. Current evidence suggests that biased agonism, through either choice of orthosteric ligands, use of allosteric modulators, direct targeting of G proteins, or manipulation of GRK and arrestin function, can be realized to tailor GPCR function and improve our ability to modulate airway inflammation and/or promote bronchodilation.
Novel strategies co-opting heterotrimeric G protein regulatory mechanisms can regulate ASM contraction
GPCRs in ASM represent attractive therapeutic targets for multiple reasons, including the ability to readily target them with selective agents (inhaled small molecules). Approaches for targeting downstream elements have some conceptual appeal; for example, broad-based strategies for inhibiting the heterotrimeric G q protein could be an effective means of negating the effects of all pro-contractile agonists in the inflamed airway, and overcoming the limitations of monotherapies such as tiotropium and montelukast [33] . To date, however, such approaches have not materialized as sufficiently selective and deliverable reagents have not been developed. However, recent studies have determined experimental approaches for manipulating heterotrimeric G protein function, many discovered as a consequence of our improved understanding of GPCR-G protein coupling, RGS function, and structural biology of heterotrimeric G proteins. We feel such approaches can be adapted to inhibit G q signaling, and consequently G q -mediated contraction, in ASM.
Multiple strategies designed to interdict GPCR-G q or G q -PLC coupling as a means of global inhibition of G q -coupled receptor signaling may offer new therapeutic approaches in airway diseases. Strategies include pepducins (Figure 2 ) that function as broad-based antagonists of G q signaling, lipidated Gα q peptides that selectively disrupt GPCR/G q coupling, and small molecule inhibitors of G bg -mediated signaling. Importantly, most of these strategies employ lipidated peptides that are amenable to delivery to the airway and ASM cells, and are more likely to specifically engage their target than are gene delivery approaches that are often required for targeting protein-protein interactions.
Our initial efforts to bias signaling with lipidated peptides focused on the development of pepducins derived from the intracellular regions of a GPCR [1] . The Benovic laboratory found that pepducins from the third intracellular loop (ICL3) of the β 2 AR could mediate G sbiased signaling [34] while pepducins from ICL1 mediated arrestin-biased signaling [35] . Some ICL3 pepducins were found to stabilize a conformation of the β 2 AR that interacted selectively with G s while other ICL3 pepducins directly activated G s . While receptorspecific ICL3 pepducins had properties attributable to G s -biased signaling such as reduced β 2 AR endocytosis and desensitization, these molecules were not effective at attenuating carbachol-induced contraction in human precision-cut lung slices [36] . Nevertheless, given the ability of pepducins to bias G s -signaling, efforts are underway to identify small molecules that would have a similar bias. Initial efforts should involve screening compounds using the β 2 AR as a target to identify G s -biased agonists, G s -biased positive allosteric modulators and arrestin-biased negative allosteric modulators.
While stimulation of G s signaling serves as a primary strategy for treating asthma, G q signaling is also an important target. However, while inhibiting human ASM contraction can serve as an effective means of treating asthma, one problem is that there are many G qcoupled receptors that are activated in asthma or COPD including the M 3 muscarinic acetylcholine, cysteinyl leukotriene, H1 histamine, thromboxane, endothelin-A/B and others.
To assess whether broad inhibition of Gq signaling is effective at attenuating ASM contraction, Carr et al. utilized several strategies to inhibit G q including the Gα q specific inhibitor FR900359 (aka UBO-QIC) and a G q -coupled receptor pepducin that appears to function as an antagonist [36] . FR900359 was confirmed as a selective G q inhibitor which does not substantially effect G s , G i or G 12/13 activity. Both the P4pal-10 pepducin and the small molecule FR900359 were effective at inhibiting G q -mediated signaling and growth in primary HASM cells, while only FR900359 effectively inhibited agonist-promoted airway contraction in human precision cut lung slices [36] . In addition the pepducin P4pal-10, derived from the intracellular loop of the protease-activated receptor (PAR) 4, was determined to function as a broad-based G q inhibitor in HEK293 and human ASM cells (Figure 3 ; data from Carr et al. [36] .) P4pal-10 was shown to inhibit G q coupling to receptors including PAR1, M 3 muscarinic acetylcholine (M 3 mAChR), and H1 histamine (H1R), whereas no direct effects on G q or the ability to antagonize GPCRs coupled to Gs were observed. Consistent with its ability to inhibit M 3 mAChR and histamine H1R coupling to Gq, p4Pal-10 inhibited ASM contraction induced by carbachol and histamine. These studies, using two approaches to inhibit G q signaling, indicate that inhibition of G q signaling at the receptor locus may be a feasible approach to treat several pathophysiological processes in airway disease. General concept of biased agonism. An unbiased agonist will induce balanced signaling by promoting coupling to G proteins and GRKs/ β-arrestins. This typically will promote G protein-dependent and β-arrestin-dependent signaling as well as GPCR desensitization, endocytosis and degradation. In contrast, a biased agonist will induce a receptor conformation that will enable selective activation of G protein -dependent or G proteinindependent (arrestin) signaling. In addition, for those GPCRs capable of coupling to multiple G proteins, biased ligands may preferentially promote GPCR coupling to a specific G protein. Accordingly, biased agonism can dramatically influence the functional consequences of receptor activation, and influence receptor desensitization. A proposed mechanism of action for pepducin effects on GPCR function. The lipidated nature of the peptides fosters pepducin incorporation into the outer leaflet of the plasmalemma. The fluidity of the pepducin to move within the plasma membrane can stabilize the GPCR conformation and/ or prevent G protein interaction to promote or inhibit intracellular signaling [1] . 
